Holen Sie sich die Stockscreener-App
3.88
0.26%
-0.01
Handel nachbörslich:
3.90
0.02
+0.52%
Schlusskurs vom Vortag:
$3.89
Offen:
$3.94
24-Stunden-Volumen:
1.34M
Relative Volume:
0.92
Marktkapitalisierung:
$299.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.62M
KGV:
-6.5276
EPS:
-0.5944
Netto-Cashflow:
$-62.34M
1W Leistung:
+8.38%
1M Leistung:
+11.98%
6M Leistung:
+150.32%
1J Leistung:
+27.21%
1-Tages-Spanne:
$3.88
$4.04
1-Wochen-Bereich:
$3.55
$4.04
52-Wochen-Spanne:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Firmenname
Eledon Pharmaceuticals Inc
Sektor
Branche
Telefon
949-238-8090
Adresse
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.88 | 300.26M | 0 | -45.62M | -62.34M | -0.5944 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Guggenheim | Buy |
| 2022-05-13 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Aktie (ELDN) Neueste Nachrichten
ELDN Technical Analysis & Stock Price Forecast - Intellectia AI
Eledon to present kidney transplant trial data at conference - Investing.com UK
Eledon to present kidney transplant trial data at conference By Investing.com - Investing.com Nigeria
Eledon to present new Phase 2 data on tegoprubart for kidney transplant rejection at June congress - Pluang
New kidney transplant rejection data from tegoprubart at ATC - Stock Titan
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TradingKey - TradingKey
BVF Group Discloses Convertible Stakes in Eledon (ELDN) — 9.99% Blockers - Stock Titan
ELDN Should I Buy - Intellectia AI
Eledon Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $8.2, Implies 111% Upside - TradingView
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Raises Target Price to $6 - Moomoo
How Should Investors Value Eledon Pharmaceuticals (ELDN) After Q - GuruFocus
Eledon (ELDN) Advances in Tegoprubart Development with Key Miles - GuruFocus
Eledon Pharmaceuticals (ELDN) Reports Q1 Loss, Cash Reserves Dec - GuruFocus
Eledon Pharma Expects Cash, Cash Equivalents and Short-Term Investments to Fund Ops Into 2Q 2027 >ELDN - Moomoo
Eledon Pharmaceuticals 1Q Loss/Shr 33c >ELDN - Moomoo
Eledon Pharmaceuticals reports Q1 EPS (33c), consensus (23c) - TipRanks
Eledon Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eledon Pharmaceuticals Q1 net loss widens on warrant liability loss - TradingView
Eledon Pharmaceuticals (ELDN) deepens Q1 2026 loss as R&D rises but cash totals $111M - Stock Titan
[8-K] Eledon Pharmaceuticals, Inc. Reports Material Event - Stock Titan
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Experimental drug helps 10 transplant patients ditch insulin entirely - Stock Titan
[EFFECT] Eledon Pharmaceuticals, Inc. SEC Filing - Stock Titan
Number of shareholders of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
[S-3] Eledon Pharmaceuticals, Inc. Shelf Registration Statement - Stock Titan
SEC Form DEFA14A filed by Eledon Pharmaceuticals Inc. - Quantisnow
[ARS] Eledon Pharmaceuticals, Inc. SEC Filing - Stock Titan
Major share authorization increase on ballot in Eledon (NASDAQ: ELDN) 2026 proxy - Stock Titan
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 - The Manila Times
NewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth Plans - Quiver Quantitative
NewcelX Reports Financial Results for 2025 and Provides Shareholders With Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration With Eledon Pharmaceuticals in 2026 - 富途牛牛
Eledon Pharmaceuticals (ELDN) Price Target Decreased by 14.93% to 8.33 - MSN
We fact-checked the hype behind the Eledon Pharmaceuticals Type 1 diabetes treatment - Healthcare Brew
BlackRock (NYSE) reports 4.38M-share stake in Eledon (ELDN) - Stock Titan
Eledon Pharmaceuticals drops 10% on stock offering - MSN
ELDN Price Today: Eledon Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Eledon Pharmaceuticals (NASDAQ: ELDN) proposes 450M-share authorization increase - Stock Titan
Eledon Pharmaceuticals (ELDN) Partners with NewcelX to Enhance D - GuruFocus
5 Unstoppable Stocks That Could Double Your Money - Insider Monkey
Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money - Insider Monkey
NewcelX Ltd. Enhances Type 1 Diabetes Program with Strategic Collaboration with Eledon Pharmaceuticals - Quiver Quantitative
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference - marketscreener.com
NewcelX heads to Swiss Biotech with a Type 1 diabetes strategy - Stock Titan
We're Not Very Worried About Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Rate - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 14.5% in March - MarketBeat
Big Picture: Can Eledon Pharmaceuticals Inc outperform under higher oil pricesWeekly Trade Review & AI Forecast for Swing Trade Picks - baoquankhu1.vn
EPS Watch: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingWeekly Market Outlook & Short-Term Swing Trade Alerts - baoquankhu1.vn
SG Americas Securities LLC Makes New Investment in Eledon Pharmaceuticals, Inc. $ELDN - MarketBeat
Finanzdaten der Eledon Pharmaceuticals Inc-Aktie (ELDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):